Summary
The kinetics of ergotamine has been investigated in migrainous patients using a new, specific, sensitive HPLC assay (detection limit 100 pg/ml plasma). 10 patients were given ergotamine tartrate 0.5 mg i.v. and 5 of them received the same dose i.m. 2–3 weeks later. Blood samples were collected for up to 54 h following administration and the plasma concentration were analysed. After intravenous administration the plasma ergotamine declined rapidly, with an initial distribution half-life of 3 min followed by a mean terminal half-life of 1.86 h (range 90–155 min). The mean total plasma clearance was 11.0 ml kg−1 min−1, and the volume of distribution (Vdβ ) was 1847.6 ml kg−1. Individual t1/2β showed a positive linear correlation with the individual Vdβ . The intramuscular absorption of ergotamine was rapid and maximum plasma levels were usually obtained 10 min following administration. The biological availability was incomplete and variable at 46.6% (range 28.3–60.8%).
Similar content being viewed by others
References
Aellig WH, Nüesch E (1977) Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration in man. Int J Clin Pharmacol 15: 106–112
Ala-Hurual V, Myllylä VV, Arvela P, Heikkilä J, Kärki N, Hokkanen E (1979) Systemic Availability of Ergotamine Tartrate after oral, rectal and intramuscular administration. Eur J Clin Pharmacol 15: 51–55
Ala-Hurual V, Myllylä VV, Arvela P, Kärki NT, Hokkanen E (1979) Systemic Availability of Ergotamine tartrate after three successive doses and during continuous medication. Eur J Clin Pharmacol 16: 355–360
British Pharmacopoeia (1980) Vol II: 607–608
Brazil P, Friedman AP (1957) Further observations in craniovascular studies. Neurology 7: 52–55
Brooke OG, Robinson BF (1970) Effect of ergotamine and ergometrine on forearm venous compliance in man. Br Med J 1: 139–142
Edlund PO (1981) Determination of ergot alkaloids in plasma by high performance liquid chromatography and fluorescence detection. J Chromatogr 226: 107–115
Elfving GL, Metzler CM (1978) Reported at 125th annual meeting of APHA (Academy of pharmaceutical sciences) Montreal
Graham JR, Wolf HG (1938) Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatr 39: 737–763
Lemaire M (1981) Personal Communication. Sandoz, Basle, Switzerland
Meier J, Schreier E (1976) Human plasma levels of some antimigraine drugs. Headache 16: 96–104
Mäntylä R, Kleimola T, Kanto J (1978) Methylergometrine (methylergonovine) concentrations in the human plasma and urine. Int J Clin Pharmacol Biopharm 16: 254–257
Orton D (1978) Ergotamine Tartrate Levels Using Radioimmunoassay. In: Green R (ed) Current Concepts in Migraine Research. Raven Press, New York, pp 79–84
Rall TW, Schleifer LS (1980) Oxytocin, prostaglandins, Ergot Alkaloids, and other agents. In: Gilman AG, Goodman LS, Gilman A (eds) The pharmacological basis of therapeutics, 6th edn. Macmillan, New York, p946
Rosentahler J, Munzer H (1976) 9, 10 Dihydroergotamine: Production of antibodies and radioimmunoassay. Experientia 32: 234–236
Schran HF, Schwarz HJ, Talbot KC, Loeffler LJ (1979) Specific Radioimmunoassay of Ergot peptide Alkaloids in plasma. Clin Chem 25: 1928–1933
Schran HF, Suryakant IB, Schwarz HJ, Thorner MO (1980) The pharmacokinetics of Bromocriptine in man. In: Goldstein M, Cal B, Lieberman A, Thorner MO (eds) Ergot compounds and brain function. Raven Press, New York, pp 125–139
Tfelt-Hansen P, Eickhoff JH, Olesen J (1980) The effect of single dose ergotamine tartrate on peripheral arteries in migraine patients: Methodological aspects and time effect curve. Acta Pharmacol Toxicol 47: 151–156
Wagner JG (1975) Fundamentals of clinical pharmacokinetics. Drug Intelligence Publication, Hamilton
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ibraheem, J.J., Paalzow, L. & Tfelt-Hansen, P. Kinetics of ergotamine after intravenous and intramuscular administration to migraine sufferers. Eur J Clin Pharmacol 23, 235–240 (1982). https://doi.org/10.1007/BF00547560
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00547560